Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
53.78
-3.76 (-6.53%)
Mar 5, 2026, 4:00 PM EST - Market closed
Spruce Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 0.7 | 4.91 | 10.09 | - | - | - | |
| Revenue Growth (YoY) | -90.18% | -51.32% | - | - | - | - | |
| Cost of Revenue | 36.88 | 46.42 | 49.43 | 35.2 | - | - | |
| Gross Profit | -36.18 | -41.51 | -39.34 | -35.2 | - | - | |
| Selling, General & Admin | 13.31 | 14.64 | 12.65 | 12.09 | 11.37 | 5.56 | |
| Research & Development | - | - | - | - | 30.7 | 23.85 | |
| Operating Expenses | 13.31 | 14.64 | 12.65 | 12.09 | 42.07 | 29.42 | |
| Operating Income | -49.49 | -56.15 | -51.99 | -47.28 | -42.07 | -29.42 | |
| Interest Expense | -0.14 | -0.31 | -0.48 | -0.42 | -0.35 | -0.32 | |
| Interest & Investment Income | 1.75 | 3.42 | 4.56 | 1.52 | 0.12 | 0.2 | |
| Pretax Income | -47.88 | -53.04 | -47.92 | -46.18 | -42.29 | -29.54 | |
| Net Income | -47.88 | -53.04 | -47.92 | -46.18 | -42.29 | -29.54 | |
| Net Income to Common | -47.88 | -53.04 | -47.92 | -46.18 | -42.29 | -29.54 | |
| Shares Outstanding (Basic) | 1 | 1 | 1 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 0 | 0 | 0 | |
| Shares Change (YoY) | 5.97% | 7.15% | 63.68% | 0.71% | 289.93% | 683.78% | |
| EPS (Basic) | -82.48 | -96.39 | -93.32 | -147.21 | -135.78 | -369.78 | |
| EPS (Diluted) | -82.48 | -96.39 | -93.32 | -147.21 | -135.78 | -369.78 | |
| Free Cash Flow | -47.55 | -55.96 | -33.28 | -41.69 | -35.97 | -27.59 | |
| Free Cash Flow Per Share | -81.91 | -101.72 | -64.82 | -132.90 | -115.48 | -345.42 | |
| Operating Margin | -7100.00% | -1143.37% | -515.34% | - | - | - | |
| Profit Margin | -6869.30% | -1079.94% | -474.96% | - | - | - | |
| Free Cash Flow Margin | -6821.81% | -1139.56% | -329.88% | - | - | - | |
| EBITDA | -49.46 | -56.11 | -51.92 | -47.21 | -42 | -29.38 | |
| D&A For EBITDA | 0.03 | 0.05 | 0.07 | 0.07 | 0.07 | 0.04 | |
| EBIT | -49.49 | -56.15 | -51.99 | -47.28 | -42.07 | -29.42 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.